- Investing Ideas
- U.S. Pharmaceuticals & Biotech Strong Balance Sheet with Growth Potential
U.S. Pharmaceuticals & Biotech Strong Balance Sheet with Growth Potential
Results
6
Stocks with plenty of capacity to fund future growth
6 companies
Corcept Therapeutics
Market Cap: US$13.4b
A biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
CORT
US$119.80
7D
0.7%
1Y
71.8%
Krystal Biotech
Market Cap: US$10.5b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
KRYS
US$359.76
7D
4.8%
1Y
143.7%
Protagonist Therapeutics
Market Cap: US$9.7b
Operates as a discovery and development company in the United States.
PTGX
US$151.50
7D
-2.2%
1Y
146.6%
Kiniksa Pharmaceuticals International
Market Cap: US$6.3b
A biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
KNSA
US$78.68
7D
-2.6%
1Y
133.5%
Vericel
Market Cap: US$2.2b
A commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.
VCEL
US$42.44
7D
-2.6%
1Y
18.3%
Zevra Therapeutics
Market Cap: US$715.0m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$11.74
7D
-3.2%
1Y
25.4%